BRAIN Biotech AG (BNN) — Cash Flow-to-Debt Ratio
BRAIN Biotech AG (BNN) has a Cash Flow-to-Debt Ratio of -0.07x as of September 2025, meaning its operating cash flow of €-4.28 Million could theoretically repay 0% of its total liabilities (€64.50 Million) in one year. Explore BNN strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BRAIN Biotech AG Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for BRAIN Biotech AG across 14 annual periods. Also explore BNN total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for BRAIN Biotech AG (2012–2025)
Year-by-year debt coverage analysis for BRAIN Biotech AG. For market capitalisation and broader financial context, see BRAIN Biotech AG market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.14x | €-9.23 Million | €64.50 Million | ▼ -199.1% |
| 2024 | -0.05x | €-3.58 Million | €74.85 Million | ▲ +45.6% |
| 2023 | -0.09x | €-4.22 Million | €47.92 Million | ▼ -159.3% |
| 2022 | -0.03x | €-1.49 Million | €43.74 Million | ▲ +68.8% |
| 2021 | -0.11x | €-3.91 Million | €35.91 Million | ▼ -5.0% |
| 2020 | -0.10x | €-4.77 Million | €46.01 Million | ▼ -50.3% |
| 2019 | -0.07x | €-3.38 Million | €49.03 Million | ▲ +44.2% |
| 2018 | -0.12x | €-5.42 Million | €43.83 Million | ▲ +54.6% |
| 2017 | -0.27x | €-5.76 Million | €21.14 Million | ▲ +35.4% |
| 2016 | -0.42x | €-8.68 Million | €20.59 Million | ▼ -152.8% |
| 2015 | -0.17x | €-4.11 Million | €24.65 Million | ▲ +52.0% |
| 2014 | -0.35x | €-3.90 Million | €11.22 Million | ▲ +46.2% |
| 2013 | -0.65x | €-4.85 Million | €7.51 Million | ▲ +16.7% |
| 2012 | -0.78x | €-5.89 Million | €7.59 Million | — |